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background:  Triglyceride (TG) rich lipoproteins have emerged as causal risk factors for the development of coronary heart disease (CHD) 
independent of circulating low-density lipoprotein cholesterol levels. Apolipoprotein C-III (ApoC-III) is a modulator of TG metabolism through 
inhibition of lipoprotein lipase and suppression of plasma TG lipolysis. Mutations causing loss-of-function of ApoC-III are associated with 
both lower TG and lower incidence of CHD, suggestive of a causal role for ApoC-III. Few studies have evaluated the relationship of ApoC-
III, TG, and atherosclerosis specifically in type 2 diabetes mellitus (T2DM) patients.
Methods:  We examined the relationship between plasma ApoC-III and TG levels as well as with coronary artery calcification (CAC) in 
patients with T2DM. Plasma ApoC-III levels were measured enzymatically (Hitachi 912, Roche Diagnostics) in a cross-sectional study of 
1422 subjects with T2DM but without clinically manifest CHD.
Results:  ApoC-III levels were positively associated with total cholesterol (Spearman r=0.36), TG (r=0.58), low-density lipoprotein 
cholesterol (r=0.16), fasting glucose (r=0.16) and glycosylated hemoglobin (r=0.12) (P < 0.0001 for all). In age, gender, and race-adjusted 
analysis, ApoC-III was associated with CAC (Tobit regression ratio 1.78, 95% CI 1.27-2.50 per standard deviation increase in ApoC-
III, P <0.001). Similar findings were noted in a sensitivity analysis of CAC as a dichotomous variable (present vs. absent) (Odds ratio = 
1.33, 95% CI 1.05-1.69, P<0.05). As expected for an intermediate mediator, these findings were attenuated when adjusted for TG (Tobit 
regression ratio 1.39, 95% CI 0.93-2.36, P=0.107).
conclusion:  Increased plasma ApoC-III is associated with higher TG, less favorable cardiometabolic phenotypes and higher CAC, a 
measure of subclinical atherosclerosis, in T2DM subjects in this large cross-sectional study. Therapeutic inhibition of plasma ApoC-III may 
thus be a novel strategy for reducing plasma TG and cardiovascular risk particularly in the T2DM setting.
